Until recently gadolinium chelates were thought to be safe when used as contrast agents for MRI. These compounds are now known to be associated with artifactual results of laboratory tests, acute kidney injury and nephrogenic systemic fibrosis, complications that seem to exclusively affect people with impaired renal function. Penfield and Reilly provide the information that physicians need to determine the relative risks and benefits of administering gadolinium to patients with chronic kidney disease.
- Jeffrey G Penfield
- Robert F Reilly Jr